Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 33
Filtrar
1.
Sci Rep ; 14(1): 8905, 2024 04 17.
Artigo em Inglês | MEDLINE | ID: mdl-38632282

RESUMO

Glyphosate is the active ingredient of glyphosate-based herbicides and the most commonly used pesticide in the world. The goal of the present study was to verify whether low doses of glyphosate (equivalent to the environmental exposure) evoke changes in galanin expression in intramural neurons in the small intestine in pigs and to quantitatively determine changes in the level of galanin receptor encoding mRNA (GALR1, GALR2, GALR3) in the small intestine wall. The experiment was conducted on 15 sexually immature gilts divided into three study groups: control (C)-animals receiving empty gelatin capsules; experimental 1 (G1)-animals receiving a low dose of glyphosate (0.05 mg/kg b.w./day); experimental 2 (G2)-animals receiving a higher dose of glyphosate (0.5 mg/kg b.w./day) orally in gelatine capsules for 28 days. Glyphosate ingestion led to an increase in the number of GAL-like immunoreactive intramural neurons in the porcine small intestine. The results of RT-PCR showed a significant increase in the expression of mRNA, which encodes the GAL-receptors in the ileum, a decreased expression in the duodenum and no significant changes in the jejunum. Additionally, intoxication with glyphosate increased the expression of SOD2-encoding mRNA in the duodenum and decreased it in the jejunum and ileum, but it did not affect SOD1 expression. The results suggest that it may be a consequence of the cytotoxic and/or neurotoxic properties of glyphosate and/or its ability to induce oxidative stress.


Assuntos
Galanina , Glifosato , Animais , Feminino , Galanina/metabolismo , Glifosato/metabolismo , Glifosato/toxicidade , Intestino Delgado/efeitos dos fármacos , Intestino Delgado/metabolismo , Receptor Tipo 2 de Galanina/efeitos dos fármacos , Receptor Tipo 2 de Galanina/genética , Receptor Tipo 2 de Galanina/metabolismo , RNA Mensageiro/metabolismo , Sus scrofa/genética , Suínos , Receptor Tipo 1 de Galanina/efeitos dos fármacos , Receptor Tipo 1 de Galanina/genética , Receptor Tipo 1 de Galanina/metabolismo , Receptor Tipo 3 de Galanina/efeitos dos fármacos , Receptor Tipo 3 de Galanina/genética , Receptor Tipo 3 de Galanina/metabolismo , Herbicidas/toxicidade
2.
Pharmacol Res ; 188: 106675, 2023 02.
Artigo em Inglês | MEDLINE | ID: mdl-36693600

RESUMO

The neuropeptide galanin receptor 3 (GALR3) is a class A G protein-coupled receptor (GPCR) broadly expressed in the nervous system, including the retina. GALR3 is involved in the modulation of immune and inflammatory responses. Tight control of these processes is critical for maintaining homeostasis in the retina and is required to sustain vision. Here, we investigated the role of GALR3 in retina pathologies triggered by bright light and P23H mutation in the rhodopsin (RHO) gene, associated with the activation of oxidative stress and inflammatory responses. We used a multiphase approach involving pharmacological inhibition of GALR3 with its antagonist SNAP-37889 and genetic depletion of GALR3 to modulate the GALR3 signaling. Our in vitro experiments in the retinal pigment epithelium-derived cells (ARPE19) susceptible to all-trans-retinal toxicity indicated that GALR3 could be involved in the cellular stress response to this phototoxic product. Indeed, blocking the GALR3 signaling in Abca4-/-/Rdh8-/- and wild-type Balb/cJ mice, sensitive to bright light-induced retina damage, protected retina health in these mice exposed to light. The retina morphology and function were substantially improved, and stress response processes were reduced in these mouse models compared to the controls. Furthermore, in P23H Rho knock-in mice, a model of retinitis pigmentosa (RP), both pharmacological inhibition and genetic ablation of GALR3 prolonged the survival of photoreceptors. These results indicate that GALR3 signaling contributes to acute light-induced and chronic RP-linked retinopathies. Together, this work provides the pharmacological knowledge base to evaluate GALR3 as a potential target for developing novel therapies to combat retinal degeneration.


Assuntos
Degeneração Retiniana , Retinose Pigmentar , Camundongos , Animais , Degeneração Retiniana/tratamento farmacológico , Degeneração Retiniana/genética , Receptor Tipo 3 de Galanina/genética , Retinose Pigmentar/genética , Retinose Pigmentar/patologia , Retina/patologia , Mutação , Modelos Animais de Doenças , Transportadores de Cassetes de Ligação de ATP/genética
3.
Molecules ; 26(7)2021 Apr 01.
Artigo em Inglês | MEDLINE | ID: mdl-33915732

RESUMO

The neuropeptide galanin (GAL), which is expressed in limbic brain structures, has a strong impact on the regulation of mood and behavior. GAL exerts its effects via three G protein-coupled receptors (GAL1-3-R). Little is known about the effects of aging and loss of GAL-Rs on hippocampal-mediated processes connected to neurogenesis, such as learning, memory recall and anxiety, and cell proliferation and survival in the dorsal dentate gyrus (dDG) in mice. Our results demonstrate that loss of GAL3-R, but not GAL2-R, slowed learning and induced anxiety in older (12-14-month-old) mice. Lack of GAL2-R increased cell survival (BrdU incorporation) in the dDG of young mice. However, normal neurogenesis was observed in vitro using neural stem and precursor cells obtained from GAL2-R and GAL3-R knockouts upon GAL treatment. Interestingly, we found sub-strain differences between C57BL/6J and C57BL/6N mice, the latter showing faster learning, less anxiety and lower cell survival in the dDG. We conclude that GAL-R signaling is involved in cognitive functions and can modulate the survival of cells in the neurogenic niche, which might lead to new therapeutic applications. Furthermore, we observed that the mouse sub-strain had a profound impact on the behavioral parameters analyzed and should therefore be carefully considered in future studies.


Assuntos
Ansiedade/etiologia , Suscetibilidade a Doenças , Aprendizagem/fisiologia , Memória/fisiologia , Receptor Tipo 2 de Galanina/genética , Receptor Tipo 3 de Galanina/genética , Fatores Etários , Envelhecimento/genética , Envelhecimento/metabolismo , Envelhecimento/psicologia , Animais , Ansiedade/metabolismo , Ansiedade/psicologia , Biomarcadores , Giro Denteado/metabolismo , Modelos Animais de Doenças , Expressão Gênica , Imuno-Histoquímica , Aprendizagem em Labirinto , Camundongos , Camundongos Knockout , Neuropeptídeos/metabolismo , Receptor Tipo 2 de Galanina/metabolismo , Receptor Tipo 3 de Galanina/metabolismo , Aprendizagem Espacial , Especificidade da Espécie
4.
Sci Rep ; 11(1): 564, 2021 01 12.
Artigo em Inglês | MEDLINE | ID: mdl-33436730

RESUMO

The regulatory (neuro)peptide galanin and its three receptors (GAL1-3R) are involved in immunity and inflammation. Galanin alleviated inflammatory bowel disease (IBD) in rats. However, studies on the galanin receptors involved are lacking. We aimed to determine galanin receptor expression in IBD patients and to evaluate if GAL2R and GAL3R contribute to murine colitis. Immunohistochemical analysis revealed that granulocytes in colon specimens of IBD patients (Crohn's disease and ulcerative colitis) expressed GAL2R and GAL3R but not GAL1R. After colitis induction with 2% dextran sulfate sodium (DSS) for 7 days, mice lacking GAL3R (GAL3R-KO) lost more body weight, exhibited more severe colonic inflammation and aggravated histologic damage, with increased infiltration of neutrophils compared to wild-type animals. Loss of GAL3R resulted in higher local and systemic inflammatory cytokine/chemokine levels. Remarkably, colitis-associated changes to the intestinal microbiota, as assessed by quantitative culture-independent techniques, were most pronounced in GAL3R-KO mice, characterized by elevated numbers of enterobacteria and bifidobacteria. In contrast, GAL2R deletion did not influence the course of colitis. In conclusion, granulocyte GAL2R and GAL3R expression is related to IBD activity in humans, and DSS-induced colitis in mice is strongly affected by GAL3R loss. Consequently, GAL3R poses a novel therapeutic target for IBD.


Assuntos
Colite Ulcerativa/genética , Colite Ulcerativa/microbiologia , Doença de Crohn/genética , Doença de Crohn/microbiologia , Microbioma Gastrointestinal , Expressão Gênica , Receptor Tipo 3 de Galanina/fisiologia , Animais , Colite Ulcerativa/terapia , Doença de Crohn/terapia , Humanos , Inflamação , Camundongos Endogâmicos C57BL , Camundongos Knockout , Terapia de Alvo Molecular , Ratos , Receptor Tipo 3 de Galanina/genética , Receptor Tipo 3 de Galanina/metabolismo
5.
Mol Cell Endocrinol ; 518: 110991, 2020 12 01.
Artigo em Inglês | MEDLINE | ID: mdl-32841709

RESUMO

The function of the gonadotropin-releasing hormone (GnRH) neuron is critical to maintain reproductive function and a significant decrease in GnRH can lead to disorders affecting fertility, including hypogonadotropic hypogonadism. Spexin (SPX) is a novel hypothalamic neuropeptide that exerts inhibitory effects on reproduction and feeding by acting through galanin receptor 2 (GALR2) and galanin receptor 3 (GALR3). Fatty acids can act as nutritional signals that regulate the hypothalamic-pituitary-gonadal (HPG) axis, and elevated levels of circulating saturated fatty acids associated with high fat diet (HFD)-feeding have been shown to induce neuroinflammation, endoplasmic reticulum stress and hormonal resistance in the hypothalamus, as well as alter neuropeptide expression. We previously demonstrated that palmitate, the most common saturated fatty acid in a HFD, elevates the expression of Spx, Galr2 and Galr3 mRNA in a model of appetite-regulating neuropeptide Y hypothalamic neurons. Here, we found that Spx, Galr2 and Galr3 mRNA were also significantly induced by palmitate in a model of reproductive GnRH neurons, mHypoA-GnRH/GFP. As a follow-up to our previous report, we examined the molecular pathways by which Spx and galanin receptor mRNA was regulated in this cell line. Furthermore, we performed inhibitor studies, which revealed that the effect of palmitate on Spx and Galr3 mRNA involved activation of the innate immune receptor TLR4, and we detected differential regulation of the three genes by the protein kinases PKC, JNK, ERK, and p38. However, the intracellular metabolism of palmitate to ceramide did not appear to be involved in the palmitate-mediated gene regulation. Overall, this suggests that SPX may play a role in reproduction at the level of the hypothalamus and the pathways by which Spx, Galr2 and Galr3 are altered by fatty acids could provide insight into the mechanisms underlying reproductive dysfunction in obesity.


Assuntos
Hormônio Liberador de Gonadotropina/metabolismo , Neurônios/citologia , Palmitatos/farmacologia , Hormônios Peptídicos/genética , Receptor Tipo 2 de Galanina/genética , Receptor Tipo 3 de Galanina/genética , Animais , Linhagem Celular , Feminino , Regulação da Expressão Gênica/efeitos dos fármacos , Hipotálamo/metabolismo , Camundongos , Proteínas Quinases Ativadas por Mitógeno/genética , Proteínas Quinases Ativadas por Mitógeno/metabolismo , Neurônios/efeitos dos fármacos , Neurônios/metabolismo , Hormônios Peptídicos/metabolismo , Proteína Quinase C/genética , Proteína Quinase C/metabolismo , Receptor Tipo 2 de Galanina/metabolismo , Receptor Tipo 3 de Galanina/metabolismo , Transdução de Sinais/efeitos dos fármacos , Receptor 4 Toll-Like/genética , Receptor 4 Toll-Like/metabolismo , Regulação para Cima
6.
PLoS One ; 15(3): e0230872, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32231393

RESUMO

Galanin receptors (GALRs) belong to the superfamily of G-protein coupled receptors. The three GALR subtypes (GALR1, GALR2, and GALR3) are activated by their endogenous ligands: spexin (SPX) and galanin (GAL). The synthetic SPX-based GALR2-specific agonist, SG2A, plays a dual role in the regulation of appetite and depression-like behaviors. Little is known, however, about the molecular interaction between GALR2 and SG2A. Using site-directed mutagenesis and domain swapping between GALR2 and GALR3, we identified residues in GALR2 that promote interaction with SG2A and residues in GALR3 that inhibit interaction with SG2A. In particular, Phe103, Phe106, and His110 in the transmembrane helix 3 (TM3) domain; Val193, Phe194, and Ser195 in the TM5 domain; and Leu273 in the extracellular loop 3 (ECL3) domain of GALR2 provide favorable interactions with the Asn5, Ala7, Phe11, and Pro13 residues of SG2A. Our results explain how SG2A achieves selective interaction with GALR2 and inhibits interaction with GALR3. The results described here can be used broadly for in silico virtual screening of small molecules for the development of GALR subtype-specific agonists and/or antagonists.


Assuntos
Receptor Tipo 2 de Galanina/química , Receptor Tipo 2 de Galanina/metabolismo , Receptor Tipo 3 de Galanina/química , Receptor Tipo 3 de Galanina/metabolismo , Sequência de Aminoácidos , Animais , Células HEK293 , Humanos , Ligantes , Camundongos , Mutação , Domínios Proteicos , Receptor Tipo 3 de Galanina/genética , Especificidade por Substrato
7.
Artigo em Inglês | MEDLINE | ID: mdl-32265844

RESUMO

Expression of neuropeptides and their corresponding receptors has been demonstrated in different cancer types, where they can play a role in tumor cell growth, invasion, and migration. Human galanin (GAL) is a 30-amino-acid regulatory neuropeptide which acts through three G protein-coupled receptors, GAL1-R, GAL2-R, and GAL3-R that differ in their signal transduction pathways. GAL and galanin receptors (GALRs) are expressed by different tumors, and direct involvement of GAL in tumorigenesis has been shown. Despite its strong expression in the central nervous system (CNS), the role of GAL in CNS tumors has not been extensively studied. To date, GAL peptide expression, GAL receptor binding and mRNA expression have been reported in glioma, meningioma, and pituitary adenoma. However, data on the cellular distribution of GALRs are sparse. The aim of the present study was to examine the expression of GAL and GALRs in different brain tumors by immunohistochemistry. Anterior pituitary gland (n = 7), pituitary adenoma (n = 9) and glioma of different WHO grades I-IV (n = 55) were analyzed for the expression of GAL and the three GALRs with antibodies recently extensively validated for specificity. While high focal GAL immunoreactivity was detected in up to 40% of cells in the anterior pituitary gland samples, only one pituitary adenoma showed focal GAL expression, at a low level. In the anterior pituitary, GAL1-R and GAL3-R protein expression was observed in up to 15% of cells, whereas receptor expression was not detected in pituitary adenoma. In glioma, diffuse and focal GAL staining was noticed in the majority of cases. GAL1-R was observed in eight out of nine glioma subtypes. GAL2-R immunoreactivity was not detected in glioma and pituitary adenoma, while GAL3-R expression was significantly associated to high-grade glioma (WHO grade IV). Most interestingly, expression of GAL and GALRs was observed in tumor-infiltrating immune cells, including neutrophils and glioma-associated macrophages/microglia. The presence of GALRs on tumor-associated immune cells, especially macrophages, indicates that GAL signaling contributes to homeostasis of the tumor microenvironment. Thus, our data indicate that GAL signaling in tumor-supportive myeloid cells could be a novel therapeutic target.


Assuntos
Adenoma/patologia , Biomarcadores Tumorais/metabolismo , Neoplasias Encefálicas/patologia , Galanina/metabolismo , Glioma/patologia , Neoplasias Hipofisárias/patologia , Receptores de Galanina/metabolismo , Adenoma/genética , Adenoma/metabolismo , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Biomarcadores Tumorais/genética , Neoplasias Encefálicas/genética , Neoplasias Encefálicas/metabolismo , Criança , Pré-Escolar , Galanina/genética , Regulação Neoplásica da Expressão Gênica , Glioma/genética , Glioma/metabolismo , Humanos , Pessoa de Meia-Idade , Neoplasias Hipofisárias/genética , Neoplasias Hipofisárias/metabolismo , Receptor Tipo 1 de Galanina/genética , Receptor Tipo 1 de Galanina/metabolismo , Receptor Tipo 2 de Galanina/genética , Receptor Tipo 2 de Galanina/metabolismo , Receptor Tipo 3 de Galanina/genética , Receptor Tipo 3 de Galanina/metabolismo , Receptores de Galanina/genética , Adulto Jovem
8.
Neuroscience ; 447: 41-52, 2020 11 01.
Artigo em Inglês | MEDLINE | ID: mdl-31730796

RESUMO

Spexin (SPX) is a novel satiety factor that putatively binds the galanin receptors R2 and R3 (GalR2/R3). SPX reduces body weight, and circulating SPX is decreased in obesity. It is unknown how SPX and its receptors are regulated in the hypothalamus, critical for energy homeostasis. We therefore examined the regulation of hypothalamic Spx, GalR2 and GalR3 gene expression in mouse primary and immortalized hypothalamic neurons. We report that Spx, GalR2 and GalR3 mRNA levels were regulated by acute treatments of palmitate, a dietary saturated fatty acid, as well as the nitric oxide (NO) donor sodium nitroprusside (SNP), but through a pathway independent of cyclic GMP and protein kinase G. Additionally, the palmitate- and NO-mediated induction of Spx and galanin receptors was blocked with the PKC inhibitor k252c. Furthermore, palmitate induced mRNA levels of endoplasmic reticulum (ER) stress markers, including Chop, Grp78 and Bax/Bcl2, as well as C/ebp-ß, whereas SNP induced Bax/Bcl2 and C/ebp-ß. Transcriptional changes in Spx, GalR2, GalR3, C/ebp-ß and ER stress marker mRNAs were blocked by pre-treatment with at least one of the chemical chaperones PBA or TUDCA. We also describe the presence of OCT-1 and C/EBP-ß response elements in the 5' regulatory region of Spx and demonstrate that SNP increases binding of C/EBP-ß to this region, but not Oct-1 mRNA nor OCT-1 binding. Our findings suggest an acute modulation of anorexigenic SPX signaling by palmitate and NO. Furthermore, ER stress and C/EBP-ß appear to mediate the changes in Spx, GalR2 and GalR3 in hypothalamic neurons.


Assuntos
Neurônios/metabolismo , Óxido Nítrico , Palmitatos , Hormônios Peptídicos/genética , Receptor Tipo 2 de Galanina/genética , Receptor Tipo 3 de Galanina/genética , Animais , Chaperona BiP do Retículo Endoplasmático , Galanina/metabolismo , Hipotálamo/citologia , Camundongos
10.
Epilepsia ; 59(11): e166-e171, 2018 11.
Artigo em Inglês | MEDLINE | ID: mdl-30298565

RESUMO

There exists solid evidence that endogenous galanin and galanin agonists exert anticonvulsive actions mediated both by galanin 1 receptor (GAL1-R) and galanin 2 receptor (GAL2-R). We have now investigated whether depletion of the recently identified third galanin receptor, GAL3-R, and that of GAL2-R, alters the threshold to the systemically applied γ-aminobutyric acid (GABA) antagonist pentylenetetrazole (PTZ) or to intrahippocampally administered kainic acid (KA). In neither model, GAL3-KO mice differed in their latency to the first seizure, mean seizure duration, total number of seizures, or time spent in seizures compared to wild-type controls. In addition, consistent with previous data, the response to PTZ was not altered in GAL2-KO mice. In contrast, intrahippocampal KA resulted in a significantly increased number of seizures and time spent in seizures in GAL2-KO mice, although the latency to the first seizure and the duration of individual seizures was not altered. These results are consistent with the previous data showing that GAL2-R knockdown does not affect the number of perforant path stimulations required for initiating status epilepticus but significantly increases the seizure severity during the ongoing status. In conclusion, our data support a specific role of GAL2-R but not of GAL3-R in mediating the anticonvulsive actions of endogenous galanin.


Assuntos
Receptor Tipo 2 de Galanina/deficiência , Receptor Tipo 3 de Galanina/deficiência , Convulsões/genética , Animais , Modelos Animais de Doenças , Eletroencefalografia , Hipocampo/efeitos dos fármacos , Ácido Caínico/toxicidade , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Pentilenotetrazol/toxicidade , Tempo de Reação/efeitos dos fármacos , Tempo de Reação/genética , Receptor Tipo 2 de Galanina/genética , Receptor Tipo 3 de Galanina/genética , Convulsões/induzido quimicamente
11.
J Invest Dermatol ; 138(1): 199-207, 2018 01.
Artigo em Inglês | MEDLINE | ID: mdl-28844939

RESUMO

The neuropeptide galanin is distributed in the central and peripheral nervous systems and in non-neuronal peripheral organs, including the skin. Galanin acts via three G protein-coupled receptors which, except galanin receptor 1, are expressed in various skin structures. The galanin system has been associated with inflammatory processes of the skin and of several other organs. Psoriasis is an inflammatory skin disease with increased neovascularization, keratinocyte hyperproliferation, a proinflammatory cytokine milieu, and immune cell infiltration. In this study, we showed that galanin receptor 3 is present in endothelial cells in human and murine dermal vessels and is co-expressed with nestin in neo-vessels of psoriatic patients. Moreover, in a murine psoriasis model, we showed that C57/BL6 mice lacking galanin receptor 3 display a milder course of psoriasis upon imiquimod treatment, leading to decreased disease severity, delayed neo-vascularization, reduced infiltration of neutrophils, and significantly lower levels of proinflammatory cytokines compared with wild-type mice. In contrast, galanin receptor 2-knockout animals did not differ significantly from wild type mice at both the macroscopic and molecular levels in their inflammatory response to imiquimod treatment. Our data indicate that galanin receptor 3, but not galanin receptor 2, plays an important role in psoriasis-like skin inflammation.


Assuntos
Citocinas/metabolismo , Neovascularização Patológica/patologia , Infiltração de Neutrófilos , Psoríase/patologia , Receptor Tipo 3 de Galanina/metabolismo , Adulto , Animais , Modelos Animais de Doenças , Feminino , Humanos , Imiquimode/imunologia , Queratinócitos , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Pessoa de Meia-Idade , Neovascularização Patológica/genética , Nestina/metabolismo , Neutrófilos/imunologia , Psoríase/diagnóstico , Psoríase/genética , Psoríase/imunologia , Receptor Tipo 2 de Galanina/genética , Receptor Tipo 2 de Galanina/metabolismo , Receptor Tipo 3 de Galanina/genética , Índice de Gravidade de Doença , Pele/irrigação sanguínea , Pele/efeitos dos fármacos , Pele/imunologia , Pele/patologia
12.
Protein Expr Purif ; 133: 41-49, 2017 05.
Artigo em Inglês | MEDLINE | ID: mdl-28263854

RESUMO

Recent innovative approaches to stabilize and crystallize GPCRs have resulted in an unprecedented breakthrough in GPCR crystal structures as well as application of the purified receptor protein in biophysical and biochemical ligand binding assays. However, the protein optimization process to enable these technologies is lengthy and requires iterative overexpression, solubilization, purification and functional analysis of tens to hundreds of protein variants. Here, we report a new and versatile method to screen in parallel hundreds of GPCR variants in HEK293 produced virus-like particles (VLPs) for protein yield, stability, functionality and ligand binding. This approach reduces the time and resources during GPCR construct optimization by eliminating lengthy protein solubilization and purification steps and by its adaptability to many binding assay formats (label or label-free detection). We exemplified the robustness of our VLP method by screening 210 GALR3-VLP variants in a radiometric agonist-based binding assay and a subset of 88 variants in a label-free antagonist-based assay. The resulting GALR3 agonist or antagonist stabilizing variants were then further used for recombinant protein expression in transfected insect cells. The final purified protein variants were successfully immobilized on a biosensor chip and used in a surface plasmon resonance binding assay.


Assuntos
Expressão Gênica , Receptor Tipo 3 de Galanina , Proteínas Recombinantes de Fusão , Vírion , Células HEK293 , Humanos , Estabilidade Proteica , Receptor Tipo 3 de Galanina/biossíntese , Receptor Tipo 3 de Galanina/química , Receptor Tipo 3 de Galanina/genética , Proteínas Recombinantes de Fusão/biossíntese , Proteínas Recombinantes de Fusão/química , Proteínas Recombinantes de Fusão/genética , Vírion/química , Vírion/genética , Vírion/metabolismo
13.
Proc Natl Acad Sci U S A ; 113(52): E8472-E8481, 2016 12 27.
Artigo em Inglês | MEDLINE | ID: mdl-27940914

RESUMO

Major depressive disorder (MDD) is a substantial burden to patients, families, and society, but many patients cannot be treated adequately. Rodent experiments suggest that the neuropeptide galanin (GAL) and its three G protein-coupled receptors, GAL1-3, are involved in mood regulation. To explore the translational potential of these results, we assessed the transcript levels (by quantitative PCR), DNA methylation status (by bisulfite pyrosequencing), and GAL peptide by RIA of the GAL system in postmortem brains from depressed persons who had committed suicide and controls. Transcripts for all four members were detected and showed marked regional variations, GAL and galanin receptor 1 (GALR1) being most abundant. Striking increases in GAL and GALR3 mRNA levels, especially in the noradrenergic locus coeruleus and the dorsal raphe nucleus, in parallel with decreased DNA methylation, were found in both male and female suicide subjects as compared with controls. In contrast, GAL and GALR3 transcript levels were decreased, GALR1 was increased, and DNA methylation was increased in the dorsolateral prefrontal cortex of male suicide subjects, however, there were no changes in the anterior cingulate cortex. Thus, GAL and its receptor GALR3 are differentially methylated and expressed in brains of MDD subjects in a region- and sex-specific manner. Such an epigenetic modification in GALR3, a hyperpolarizing receptor, might contribute to the dysregulation of noradrenergic and serotonergic neurons implicated in the pathogenesis of MDD. Thus, one may speculate that a GAL3 antagonist could have antidepressant properties by disinhibiting the firing of these neurons, resulting in increased release of noradrenaline and serotonin in forebrain areas involved in mood regulation.


Assuntos
Transtorno Depressivo Maior/metabolismo , Galanina/metabolismo , Receptor Tipo 1 de Galanina/metabolismo , Receptor Tipo 3 de Galanina/metabolismo , Adulto , Afeto , Idoso , Encéfalo/metabolismo , Encéfalo/patologia , Mapeamento Encefálico , Estudos de Casos e Controles , Metilação de DNA , Transtorno Depressivo Maior/genética , Núcleo Dorsal da Rafe/metabolismo , Feminino , Galanina/genética , Perfilação da Expressão Gênica , Regulação da Expressão Gênica , Humanos , Locus Cerúleo/metabolismo , Masculino , Pessoa de Meia-Idade , Receptor Tipo 1 de Galanina/genética , Receptor Tipo 3 de Galanina/genética , Fatores Sexuais , Suicídio
14.
Exp Neurol ; 279: 159-167, 2016 May.
Artigo em Inglês | MEDLINE | ID: mdl-26928087

RESUMO

The symptomatology, mood and cognitive disturbances seen in post-traumatic stress disorder (PTSD) and mild blast-induced traumatic brain injury (mbTBI) overlap considerably. However the pathological mechanisms underlying the two conditions are currently unknown. The neuropeptide galanin has been suggested to play a role in the development of stress and mood disorders. Here we applied bio- and histochemical methods with the aim to elucidate the nature of any changes in the expression of galanin and its receptors in a rodent model of mbTBI. In situ hybridization and quantitative polymerase chain reaction studies revealed significant, injury-induced changes, in some cases lasting at least for one week, in the mRNA levels of galanin and/or its three receptors, galanin receptor 1-3 (GalR1-3). Such changes were seen in several forebrain regions, and the locus coeruleus. In the ventral periaqueductal gray GalR1 mRNA levels were increased, while GalR2 were decreased. Analysis of galanin peptide levels using radioimmunoassay demonstrated an increase in several brain regions including the locus coeruleus, dorsal hippocampal formation and amygdala. These findings suggest a role for the galanin system in the endogenous response to mbTBI, and that pharmacological studies of the effects of activation or inhibition of different galanin receptors in combination with functional assays of behavioral recovery may reveal promising targets for new therapeutic strategies in mbTBI.


Assuntos
Traumatismos por Explosões/metabolismo , Lesões Encefálicas/metabolismo , Galanina/biossíntese , Precursores de Proteínas/biossíntese , Receptores de Galanina/biossíntese , Animais , Traumatismos por Explosões/patologia , Lesões Encefálicas/patologia , Locus Cerúleo/metabolismo , Masculino , Prosencéfalo/metabolismo , RNA Mensageiro/biossíntese , RNA Mensageiro/genética , Núcleos da Rafe/metabolismo , Ratos , Ratos Sprague-Dawley , Receptor Tipo 1 de Galanina/biossíntese , Receptor Tipo 1 de Galanina/genética , Receptor Tipo 2 de Galanina/biossíntese , Receptor Tipo 2 de Galanina/genética , Receptor Tipo 3 de Galanina/biossíntese , Receptor Tipo 3 de Galanina/genética
15.
J Mol Neurosci ; 59(2): 260-9, 2016 06.
Artigo em Inglês | MEDLINE | ID: mdl-26941032

RESUMO

Neurogenic inflammation mediated by peptidergic sensory nerves has a crucial impact on the pathogenesis of various joint diseases. Galanin is a regulatory sensory neuropeptide, which has been shown to attenuate neurogenic inflammation, modulate neutrophil activation, and be involved in the development of adjuvant arthritis, but our current understanding about its targets and physiological importance is incomplete. Among the receptors of galanin (GAL1-3), GAL3 has been found to be the most abundantly expressed in the vasculature and on the surface of some immune cells. However, since there are minimal in vivo data on the role of GAL3 in joint diseases, we analyzed its involvement in different inflammatory mechanisms of the K/BxN serum transfer-model of autoimmune arthritis employing GAL 3 gene-deficient mice. After arthritis induction, GAL3 knockouts demonstrated increased clinical disease severity and earlier hindlimb edema than wild types. Vascular hyperpermeability determined by in vivo fluorescence imaging was also elevated compared to the wild-type controls. However, neutrophil accumulation detected by in vivo luminescence imaging or arthritic mechanical hyperalgesia was not altered by the lack of the GAL3 receptor. Our findings suggest that GAL3 has anti-inflammatory properties in joints by inhibiting vascular hyperpermeability and consequent edema formation.


Assuntos
Artrite/metabolismo , Doenças Autoimunes/metabolismo , Receptor Tipo 3 de Galanina/genética , Animais , Artrite/genética , Artrite/patologia , Doenças Autoimunes/genética , Doenças Autoimunes/patologia , Permeabilidade Capilar , Edema/metabolismo , Endotélio Vascular/metabolismo , Membro Posterior/patologia , Masculino , Camundongos , Neutrófilos/metabolismo , Receptor Tipo 3 de Galanina/deficiência
16.
Dev Neurosci ; 36(6): 454-64, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-25195605

RESUMO

Prenatal stress (PS) exposure is known to increase the risk of developing emotional disorders like major depression in later life. However, some individuals do not succumb to adversity following developmental stress exposure, a phenomenon referred to as resilience. To date, the molecular mechanisms explaining why some subjects are vulnerable and others more resilient to PS are far from understood. Recently, we have shown that the serotonin transporter (5-HTT) gene may play a modulating role in rendering individuals susceptible or resilient to PS. However, it is not clear which molecular players are mediating the interaction between PS and the 5-Htt genotype in the context of vulnerability and resilience to PS. For this purpose, we performed a microarray study with the help of Affymetrix GeneChip® Mouse Genome 430 2.0 Array, in which we separated wild-type and heterozygous 5-Htt-deficient (5-Htt+/-) PS offspring into susceptible and resilient offspring according to their performance in the forced swim test. Performance-oriented LIMMA analysis on the mRNA expression microarray data was followed by subsequent Spearman's correlation analysis linking the individual qRT-PCR mRNA expression data to various anxiety- and depression-related behavioral and neuroendocrine measures. Results indicate that, amongst others, Fos-induced growth factor (Figf), galanin receptor 3 (Galr3), growth hormone (Gh) and prolactin (Prl) were differentially expressed specifically in resilient offspring when compared to controls, and that the hippocampal expression of these genes showed several strong correlations with various measures of the hypothalamus-pituitary-adrenal axis (re)activity. In conclusion, there seems to be an intricate interplay between the expression of Figf, Galr3, Gh and Prl and neuroendocrine regulation, which may be critical in mediating resilience to PS exposure. More insight into the exact role of these molecular players may significantly enhance the development of new treatment strategies for stress-related emotional disorders.


Assuntos
Comportamento Animal/fisiologia , Cortisona/metabolismo , Predisposição Genética para Doença , Hipocampo/metabolismo , Efeitos Tardios da Exposição Pré-Natal/etiologia , Proteínas da Membrana Plasmática de Transporte de Serotonina/deficiência , Estresse Psicológico/genética , Animais , Modelos Animais de Doenças , Feminino , Perfilação da Expressão Gênica , Hormônio do Crescimento/genética , Camundongos , Gravidez , Prolactina/genética , Receptor Tipo 3 de Galanina/genética , Proteínas da Membrana Plasmática de Transporte de Serotonina/genética , Estresse Psicológico/metabolismo , Fator D de Crescimento do Endotélio Vascular/genética
17.
Proc Natl Acad Sci U S A ; 111(19): 7138-43, 2014 May 13.
Artigo em Inglês | MEDLINE | ID: mdl-24782539

RESUMO

The neuropeptide galanin (GAL) is widely distributed in the central and peripheral nervous systems. It is a modulator of various physiological and pathological processes, and it mediates its effects via three G protein-coupled receptors (GAL1-3 receptors). A role for GAL as a modulator of mood and anxiety was suggested, because GAL and its receptors are highly expressed in limbic brain structures of rodents. In recent years, numerous studies of animal models have suggested an involvement of GAL and GAL1 and GAL2 receptors in anxiety- and depression-related behavior. However, to date, there is sparse literature implicating GAL3 receptors in behavioral functions. Therefore, we studied the behavior of GAL3 receptor-deficient (GAL3-KO) mice to elucidate whether GAL3 receptors are involved in mediating behavior-associated actions of GAL. The GAL3-KO mouse line exhibited normal breeding and physical development. In addition to behavioral tests, phenotypic characterization included analysis of hematology, amino acid profiles, metabolism, and sudomotor function. In contrast to WT littermates, male GAL3-KO mice exhibited an anxiety-like phenotype in the elevated plus maze, open field, and light/dark box tests, and they were less socially affiliated than WT animals to a stranger mouse in a social interaction test. In conclusion, our data suggest involvement of GAL3 receptors in GAL-mediated effects on mood, anxiety, and behavior, making it a possible target for alternative treatment strategies for mood disorders.


Assuntos
Transtornos de Ansiedade/genética , Transtornos de Ansiedade/fisiopatologia , Transtorno Depressivo/genética , Transtorno Depressivo/fisiopatologia , Receptor Tipo 3 de Galanina/genética , Animais , Comportamento Animal/fisiologia , Feminino , Masculino , Camundongos , Camundongos Knockout , Modelos Animais , Fenótipo , Receptor Tipo 3 de Galanina/metabolismo , Serotonina/metabolismo , Comportamento Social , Glândulas Sudoríparas/fisiologia
18.
Endocrinology ; 155(5): 1864-73, 2014 May.
Artigo em Inglês | MEDLINE | ID: mdl-24517231

RESUMO

The novel neuropeptide spexin (SPX) was discovered using bioinformatics. The function of this peptide is currently under investigation. Here, we identified SPX along with a second SPX gene (SPX2) in vertebrate genomes. Syntenic analysis and relocating SPXs and their neighbor genes on reconstructed vertebrate ancestral chromosomes revealed that SPXs reside in the near vicinity of the kisspeptin (KISS) and galanin (GAL) family genes on the chromosomes. Alignment of mature peptide sequences showed some extent of sequence similarity among the 3 peptide groups. Gene structure analysis indicated that SPX is more closely related to GAL than KISS. These results suggest that the SPX, GAL, and KISS genes arose through local duplications before 2 rounds (2R) of whole-genome duplication. Receptors of KISS and GAL (GAL receptor [GALR]) are phylogenetically closest among rhodopsin-like G protein-coupled receptors, and synteny revealed the presence of 3 distinct receptor families KISS receptor, GALR1, and GALR2/3 before 2R. A ligand-receptor interaction study showed that SPXs activate human, Xenopus, and zebrafish GALR2/3 family receptors but not GALR1, suggesting that SPXs are natural ligands for GALR2/3. Particularly, SPXs exhibited much higher potency toward GALR3 than GAL. Together, these results identify the coevolution of SPX/GAL/KISS ligand genes with their receptor genes. This study demonstrates the advantage of evolutionary genomics to explore the evolutionary relationship of a peptide gene family that arose before 2R by local duplications.


Assuntos
Evolução Molecular , Galanina/metabolismo , Kisspeptinas/metabolismo , Hormônios Peptídicos/metabolismo , Receptor Tipo 2 de Galanina/agonistas , Receptor Tipo 3 de Galanina/agonistas , Animais , Mapeamento Cromossômico , Bases de Dados de Ácidos Nucleicos , Bases de Dados de Proteínas , Galanina/química , Galanina/genética , Duplicação Gênica , Células HEK293 , Humanos , Kisspeptinas/química , Kisspeptinas/genética , Ligantes , Neuropeptídeos/química , Neuropeptídeos/genética , Neuropeptídeos/metabolismo , Hormônios Peptídicos/química , Hormônios Peptídicos/genética , Filogenia , Isoformas de Proteínas/química , Isoformas de Proteínas/genética , Isoformas de Proteínas/metabolismo , Receptor Tipo 1 de Galanina/agonistas , Receptor Tipo 1 de Galanina/química , Receptor Tipo 1 de Galanina/genética , Receptor Tipo 1 de Galanina/metabolismo , Receptor Tipo 2 de Galanina/química , Receptor Tipo 2 de Galanina/genética , Receptor Tipo 2 de Galanina/metabolismo , Receptor Tipo 3 de Galanina/química , Receptor Tipo 3 de Galanina/genética , Receptor Tipo 3 de Galanina/metabolismo , Receptores Acoplados a Proteínas G/química , Receptores Acoplados a Proteínas G/genética , Receptores Acoplados a Proteínas G/metabolismo , Receptores de Kisspeptina-1 , Proteínas Recombinantes/química , Proteínas Recombinantes/metabolismo , Alinhamento de Sequência , Sintenia , Proteínas de Peixe-Zebra/química , Proteínas de Peixe-Zebra/genética , Proteínas de Peixe-Zebra/metabolismo
19.
Assay Drug Dev Technol ; 11(8): 468-77, 2013 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-24116939

RESUMO

The galanin 3 receptor (GalR3) belongs to the large G protein-coupled receptor (GPCR) family of proteins. GalR3 and two other closely related receptors, GalR1 and GalR2, together with their endogenous ligand galanin, are involved in a variety of physiological and pathophysiological processes. GalR3 in particular has been strongly implicated in addiction and mood-related disorders such as anxiety and depression. It has been the target of many drug discovery programs within the pharmaceutical industry, but despite the significant resources and effort devoted to discovery of galanin receptor subtype selective small molecule modulators, there have been very few reports for the discovery of such molecules. GalR3 has proven difficult to enable in cell-based functional assays due to its apparent poor cell surface expression in recombinant systems. Here, we describe the generation of a modified GalR3 that facilitates its cell surface expression while maintaining wild-type receptor pharmacology. The modified GalR3 has been used to develop a high-throughput screening-compatible, cell-based, cAMP biosensor assay to detect selective small molecule modulators of GalR3. The performance of the assay has been validated by challenging it against a test library of small molecules with known pharmacological activities (LOPAC; Sigma Aldrich). This approach will enable identification of GalR3 selective modulators (chemical probes) that will facilitate dissection of the biological role(s) that GalR3 plays in normal physiological processes as well as in disease states.


Assuntos
Receptor Tipo 3 de Galanina/efeitos dos fármacos , Técnicas Biossensoriais , Membrana Celular/metabolismo , Clonagem Molecular , AMP Cíclico/metabolismo , DNA Complementar/biossíntese , DNA Complementar/genética , Técnica Indireta de Fluorescência para Anticorpo , Galanina/metabolismo , Células HEK293 , Ensaios de Triagem em Larga Escala , Humanos , Ligantes , Receptor Tipo 3 de Galanina/genética , Bibliotecas de Moléculas Pequenas
20.
Proc Natl Acad Sci U S A ; 110(6): E536-45, 2013 Feb 05.
Artigo em Inglês | MEDLINE | ID: mdl-23341594

RESUMO

Using riboprobe in situ hybridization, we studied the localization of the transcripts for the neuropeptide galanin and its receptors (GalR1-R3), tryptophan hydroxylase 2, tyrosine hydroxylase, and nitric oxide synthase as well as the three vesicular glutamate transporters (VGLUT 1-3) in the locus coeruleus (LC) and the dorsal raphe nucleus (DRN) regions of postmortem human brains. Quantitative real-time PCR (qPCR) was used also. Galanin and GalR3 mRNA were found in many noradrenergic LC neurons, and GalR3 overlapped with serotonin neurons in the DRN. The qPCR analysis at the LC level ranked the transcripts in the following order in the LC: galanin >> GalR3 >> GalR1 > GalR2; in the DRN the ranking was galanin >> GalR3 >> GalR1 = GalR2. In forebrain regions the ranking was GalR1 > galanin > GalR2. VGLUT1 and -2 were strongly expressed in the pontine nuclei but could not be detected in LC or serotonin neurons. VGLUT2 transcripts were found in very small, nonpigmented cells in the LC and in the lateral and dorsal aspects of the periaqueductal central gray. Nitric oxide synthase was not detected in serotonin neurons. These findings show distinct differences between the human brain and rodents, especially rat, in the distribution of the galanin system and some other transmitter systems. For example, GalR3 seems to be the important galanin receptor in both the human LC and DRN versus GalR1 and -2 in the rodent brain. Such knowledge may be important when considering therapeutic principles and drug development.


Assuntos
Encéfalo/metabolismo , Galanina/genética , Galanina/metabolismo , Neurotransmissores/metabolismo , Animais , Humanos , Hibridização In Situ , Locus Cerúleo/metabolismo , Neurotransmissores/genética , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , Núcleos da Rafe/metabolismo , Ratos , Reação em Cadeia da Polimerase em Tempo Real , Receptor Tipo 1 de Galanina/genética , Receptor Tipo 1 de Galanina/metabolismo , Receptor Tipo 2 de Galanina/genética , Receptor Tipo 2 de Galanina/metabolismo , Receptor Tipo 3 de Galanina/genética , Receptor Tipo 3 de Galanina/metabolismo , Especificidade da Espécie , Distribuição Tecidual , Proteína Vesicular 1 de Transporte de Glutamato/genética , Proteína Vesicular 1 de Transporte de Glutamato/metabolismo , Proteína Vesicular 2 de Transporte de Glutamato/genética , Proteína Vesicular 2 de Transporte de Glutamato/metabolismo , Proteínas Vesiculares de Transporte de Glutamato/genética , Proteínas Vesiculares de Transporte de Glutamato/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...